Stevens-Johnson syndrome classification: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Stevens-Johnson syndrome}} | {{Stevens-Johnson syndrome}} | ||
{{CMG}}; {{AE}} | |||
{{CMG}} | |||
==Overview== | ==Overview== | ||
There is agreement in the medical literature that [[Stevens-Johnson syndrome]] can be considered a milder form of [[toxic epidermal necrolysis]] (TEN). However, there is debate whether it falls on a spectrum of disease that includes [[erythema multiforme]] and erythema multiforme major (also known as erythema multiforme majus).<ref>{{cite journal |author=Carrozzo M, Togliatto M, Gandolfo S |title=[Erythema multiforme. A heterogeneous pathologic phenotype] |journal=Minerva Stomatol |volume=48 |issue=5 |pages=217-26 |year=1999 |pmid=10434539}}</ref><ref>{{cite journal |author=Farthing P, Bagan J, Scully C |title=Mucosal disease series. Number IV. Erythema multiforme |journal=Oral Dis |volume=11 |issue=5 |pages=261-7 |year=2005 |pmid=16120111}}</ref><ref>{{cite journal |author=Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC |title=Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme |journal=Archives of dermatology |volume=129 |issue=1 |pages=92-6 |year=1993 |pmid=8420497 | doi = 10.1001/archderm.129.1.92 <!--Retrieved from CrossRef by DOI bot-->}}</ref><ref>Ogundele O, Silverberg MA. Erythema Multiforme. eMedicine.com. URL: [http://www.emedicine.com/emerg/topic173.htm http://www.emedicine.com/emerg/topic173.htm]. Accessed on: May 6, 2007.</ref><ref name="pmid12164739">{{cite journal | There is agreement in the medical literature that [[Stevens-Johnson syndrome]] can be considered a milder form of [[toxic epidermal necrolysis]] (TEN). However, there is debate whether it falls on a spectrum of disease that includes [[erythema multiforme]] and erythema multiforme major (also known as erythema multiforme majus).<ref>{{cite journal |author=Carrozzo M, Togliatto M, Gandolfo S |title=[Erythema multiforme. A heterogeneous pathologic phenotype] |journal=Minerva Stomatol |volume=48 |issue=5 |pages=217-26 |year=1999 |pmid=10434539}}</ref><ref>{{cite journal |author=Farthing P, Bagan J, Scully C |title=Mucosal disease series. Number IV. Erythema multiforme |journal=Oral Dis |volume=11 |issue=5 |pages=261-7 |year=2005 |pmid=16120111}}</ref><ref>{{cite journal |author=Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC |title=Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme |journal=Archives of dermatology |volume=129 |issue=1 |pages=92-6 |year=1993 |pmid=8420497 | doi = 10.1001/archderm.129.1.92 <!--Retrieved from CrossRef by DOI bot-->}}</ref><ref>Ogundele O, Silverberg MA. Erythema Multiforme. eMedicine.com. URL: [http://www.emedicine.com/emerg/topic173.htm http://www.emedicine.com/emerg/topic173.htm]. Accessed on: May 6, 2007.</ref><ref name="pmid12164739">{{cite journal | ||
Line 20: | Line 18: | ||
| issn = | | issn = | ||
}}</ref> | }}</ref> | ||
==Classification== | |||
There is no established system for the classification of [disease name]. | |||
OR | |||
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: | |||
*[Group1] | |||
*[Group2] | |||
*[Group3] | |||
*[Group4] | |||
OR | |||
[Disease name] may be classified into [large number > 6] subtypes based on: | |||
*[Classification method 1] | |||
*[Classification method 2] | |||
*[Classification method 3] | |||
[Disease name] may be classified into several subtypes based on: | |||
*[Classification method 1] | |||
*[Classification method 2] | |||
*[Classification method 3] | |||
OR | |||
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic. | |||
OR | |||
'''If the staging system involves specific and characteristic findings and features:''' | |||
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2]. | |||
OR | |||
The staging of [malignancy name] is based on the [staging system]. | |||
OR | |||
[ | There is no established system for the staging of [malignancy name]. | ||
{{ | ==References== | ||
{{ | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category: (name of the system)]] |
Revision as of 15:31, 15 August 2018
Stevens-Johnson syndrome Microchapters |
Differentiating Stevens-Johnson Syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Stevens-Johnson syndrome classification On the Web |
American Roentgen Ray Society Images of Stevens-Johnson syndrome classification |
Risk calculators and risk factors for Stevens-Johnson syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is agreement in the medical literature that Stevens-Johnson syndrome can be considered a milder form of toxic epidermal necrolysis (TEN). However, there is debate whether it falls on a spectrum of disease that includes erythema multiforme and erythema multiforme major (also known as erythema multiforme majus).[1][2][3][4][5]
Classification
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [Group1]
- [Group2]
- [Group3]
- [Group4]
OR
[Disease name] may be classified into [large number > 6] subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
[Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
References
- ↑ Carrozzo M, Togliatto M, Gandolfo S (1999). "[Erythema multiforme. A heterogeneous pathologic phenotype]". Minerva Stomatol. 48 (5): 217–26. PMID 10434539.
- ↑ Farthing P, Bagan J, Scully C (2005). "Mucosal disease series. Number IV. Erythema multiforme". Oral Dis. 11 (5): 261–7. PMID 16120111.
- ↑ Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993). "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme". Archives of dermatology. 129 (1): 92–6. doi:10.1001/archderm.129.1.92. PMID 8420497.
- ↑ Ogundele O, Silverberg MA. Erythema Multiforme. eMedicine.com. URL: http://www.emedicine.com/emerg/topic173.htm. Accessed on: May 6, 2007.
- ↑ Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC (2002). "Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study". Arch Dermatol. 138 (8): 1019–24. PMID 12164739. Unknown parameter
|month=
ignored (help)